GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (STU:BJX1) » Definitions » Cyclically Adjusted PS Ratio

BioLife Solutions (STU:BJX1) Cyclically Adjusted PS Ratio : 9.18 (As of Apr. 27, 2024)


View and export this data going back to 2017. Start your Free Trial

What is BioLife Solutions Cyclically Adjusted PS Ratio?

As of today (2024-04-27), BioLife Solutions's current share price is €15.70. BioLife Solutions's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was €1.71. BioLife Solutions's Cyclically Adjusted PS Ratio for today is 9.18.

The historical rank and industry rank for BioLife Solutions's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:BJX1' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.16   Med: 10.02   Max: 44.47
Current: 9.44

During the past years, BioLife Solutions's highest Cyclically Adjusted PS Ratio was 44.47. The lowest was 2.16. And the median was 10.02.

STU:BJX1's Cyclically Adjusted PS Ratio is ranked worse than
84.7% of 464 companies
in the Medical Devices & Instruments industry
Industry Median: 2.135 vs STU:BJX1: 9.44

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BioLife Solutions's adjusted revenue per share data for the three months ended in Dec. 2023 was €0.670. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €1.71 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


BioLife Solutions Cyclically Adjusted PS Ratio Historical Data

The historical data trend for BioLife Solutions's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLife Solutions Cyclically Adjusted PS Ratio Chart

BioLife Solutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.87 36.13 26.81 10.67 8.75

BioLife Solutions Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.67 12.31 12.17 7.46 8.75

Competitive Comparison of BioLife Solutions's Cyclically Adjusted PS Ratio

For the Medical Instruments & Supplies subindustry, BioLife Solutions's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLife Solutions's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioLife Solutions's Cyclically Adjusted PS Ratio falls into.



BioLife Solutions Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

BioLife Solutions's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=15.70/1.71
=9.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLife Solutions's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, BioLife Solutions's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.67/129.4194*129.4194
=0.670

Current CPI (Dec. 2023) = 129.4194.

BioLife Solutions Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.268 99.695 0.348
201406 0.074 100.560 0.095
201409 0.080 100.428 0.103
201412 0.115 99.070 0.150
201503 0.115 99.621 0.149
201506 0.110 100.684 0.141
201509 0.120 100.392 0.155
201512 0.136 99.792 0.176
201603 0.133 100.470 0.171
201606 0.141 101.688 0.179
201609 0.150 101.861 0.191
201612 0.166 101.863 0.211
201703 0.171 102.862 0.215
201706 0.174 103.349 0.218
201709 0.188 104.136 0.234
201712 0.193 104.011 0.240
201803 0.219 105.290 0.269
201806 0.218 106.317 0.265
201809 0.192 106.507 0.233
201812 0.259 105.998 0.316
201903 0.274 107.251 0.331
201906 0.242 108.070 0.290
201909 0.237 108.329 0.283
201912 0.362 108.420 0.432
202003 0.524 108.902 0.623
202006 0.378 108.767 0.450
202009 0.303 109.815 0.357
202012 0.367 109.897 0.432
202103 0.426 111.754 0.493
202106 0.641 114.631 0.724
202109 0.664 115.734 0.743
202112 0.573 117.630 0.630
202203 0.783 121.301 0.835
202206 0.903 125.017 0.935
202209 0.965 125.227 0.997
202212 0.875 125.222 0.904
202303 0.818 127.348 0.831
202306 0.839 128.729 0.844
202309 0.717 129.860 0.715
202312 0.670 129.419 0.670

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioLife Solutions  (STU:BJX1) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


BioLife Solutions Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of BioLife Solutions's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLife Solutions (STU:BJX1) Business Description

Traded in Other Exchanges
Address
3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.

BioLife Solutions (STU:BJX1) Headlines

No Headlines